Statins are associated with decreased mortality risk after status epilepticus

European Journal of Neurology

Volumn 22, Issue 2, 2015, Pages 402-405

  Sierra Marcos, A ^a   Alvarez, V ^a   Faouzi, M ^b   Burnand, B ^b   Rossetti, A O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Epilepsy; Hydroxymethyl CoA reductase; Outcome; Status epilepticus; Treatment

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ABSENCE; ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; COMA; COMPLEX PARTIAL SEIZURE; DISABILITY; DISEASE SEVERITY; EPILEPTIC STATE; FATALITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOCLONUS SEIZURE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SIMPLE PARTIAL SEIZURE; TONIC CLONIC SEIZURE; MIDDLE AGED; PROGNOSIS; STATUS EPILEPTICUS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROGNOSIS; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84920663612     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12428     Document Type: Article

References (14)

1. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997; 38: 1344-1349.
2. Willey JZ, Elkind MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010; 67: 1062-1067.
3. Lee JK, Won JS, Singh AK, Singh I. Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death. Neurosci Lett 2008; 440: 260-264.
4. Russo E, Donato di Paola E, Gareri P, et al. Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice. Pharmacol Res 2012; 70: 1-12.
5. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia 2010; 51: 251-256.
6. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40: 120-122.
7. Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006; 77: 611-615.
8. Alvarez V, Januel JM, Burnand B, Rossetti AO. Role of comorbidities in outcome prediction after status epilepticus. Epilepsia 2012; 53: e89-e92.
9. Tsai MH, Chuang YC, Chang HW, et al. Factors predictive of outcome in patients with de novo status epilepticus. QJM 2009; 102: 57-62.
10. Rossetti AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008; 255: 1561-1566.
11. Pugh MJ, Knoefel JE, Mortensen EM, Amuan ME, Berlowitz DR, Van Cott AC. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc 2009; 57: 237-242.
12. Etminan M, Samii A, Brophy JM. Statin use and risk of epilepsy: a nested case-control study. Neurology 2010; 75: 1496-1500.
13. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7: 31-40.
14. Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol 2013; 260: 421-428.